Page last updated: 2024-08-24

mevastatin and Hyperlipoproteinemia Type II

mevastatin has been researched along with Hyperlipoproteinemia Type II in 18 studies

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-199013 (72.22)18.7374
1990's1 (5.56)18.2507
2000's2 (11.11)29.6817
2010's2 (11.11)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blanchard, V; Blom, DJ; Bourane, S; Cariou, B; Chemello, K; Croyal, M; Farnier, M; Lambert, G; Nativel, B; Pichelin, M; Raal, FJ; Ramin-Mangata, S; Tang, L; Thedrez, A1
Blom, DJ; Chatelais, M; Gusarova, V; Lambert, G; Marais, AD; Passard, M; Petrides, F; Rye, KA; Sasiela, W; Schwahn, U; Thedrez, A1
Haba, T; Koizumi, J; Mabuchi, H; Miyamoto, S; Sakai, Y; Takeda, R; Tatami, R; Wakasugi, T; Watanabe, A2
Brown, MS; Goldstein, JL2
De Boer, HH; Hendriks, T; Van Niekerk, JL1
Matsuzawa, Y; Sudo, H; Yamamoto, A; Yamamura, T; Yokoyama, S1
Hayashi, R; Hirobe, K; Kikkawa, T; Kishino, B; Matsuzawa, Y; Yamamoto, A1
Koizumi, J; Mabuchi, H; Sakai, T; Sakai, Y; Takeda, R; Wakasugi, T; Watanabe, A; Yoshimura, A1
Haba, T; Kametani, T; Koizumi, J; Mabuchi, H; Miyamoto, S; Takeda, R; Takeshita, H; Tatami, R; Ueda, K; Ueda, R; Wakasugi, T; Watanabe, A; Yoshimura, A1
Mabuchi, H1
Kuwano, M; Ono, M1
Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S1
Knight, BL; Patel, DD; Soutar, AK1
Endo, A2
Santafé Oroz, J; Segarra Domènech, J1

Reviews

4 review(s) available for mevastatin and Hyperlipoproteinemia Type II

ArticleYear
The treatment of familial hypercholesterolaemia by partial ileal bypass surgery. A review of the literature.
    The Netherlands journal of medicine, 1984, Volume: 27, Issue:1

    Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Diarrhea; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Ileum; Lovastatin; Methods; Naphthalenes; Niacin; Postoperative Complications

1984
[Clinical studies on hyperlipidemia].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1999, Sep-10, Volume: 88, Issue:9

    Topics: Acyl Coenzyme A; Anticholesteremic Agents; Blood Component Removal; Clinical Trials as Topic; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lovastatin

1999
Somatic cell mutants of low density lipoprotein receptor.
    Cell structure and function, 1989, Volume: 14, Issue:5

    Topics: Animals; Carbohydrate Sequence; Cell Line; Hyperlipoproteinemia Type II; Lovastatin; Molecular Sequence Data; Monensin; Mutation; Receptors, LDL

1989
[Pharmacologic therapy of arteriosclerosis. II. New directions].
    Medicina clinica, 1985, Jan-26, Volume: 84, Issue:3

    Topics: Animals; Anticholesteremic Agents; Arachidonate Lipoxygenases; Arteriosclerosis; Blood Platelets; Cholesterol; Cholesterol Esters; Cholesterol, LDL; Enzyme Induction; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoxygenase Inhibitors; Lovastatin; Male; Models, Biological; Muscle, Smooth, Vascular; Naphthalenes; Phosphatidylcholine-Sterol O-Acyltransferase; Platelet Aggregation; Rats; Receptors, LDL

1985

Trials

1 trial(s) available for mevastatin and Hyperlipoproteinemia Type II

ArticleYear
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Arteriosclerosis, thrombosis, and vascular biology, 2018, Volume: 38, Issue:3

    Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoprotein B-100; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Receptors, LDL; Serine Proteinase Inhibitors; Treatment Outcome; Young Adult

2018

Other Studies

13 other study(ies) available for mevastatin and Hyperlipoproteinemia Type II

ArticleYear
Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
    Journal of the American College of Cardiology, 2014, Dec-02, Volume: 64, Issue:21

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cells, Cultured; Fibroblasts; Flow Cytometry; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; Serine Endopeptidases

2014
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
    Atherosclerosis. Supplements, 2004, Volume: 5, Issue:3

    Topics: Anticholesteremic Agents; Coenzymes; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Ubiquinone

2004
Lowering plasma cholesterol by raising ldl receptors. 1981.
    Atherosclerosis. Supplements, 2004, Volume: 5, Issue:3

    Topics: Animals; Anticholesteremic Agents; Cholesterol; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Receptors, LDL

2004
Lowering plasma cholesterol by raising LDL receptors.
    The New England journal of medicine, 1981, Aug-27, Volume: 305, Issue:9

    Topics: Animals; Cholesterol; Dogs; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Middle Aged; Naphthalenes; Receptors, Cell Surface; Receptors, LDL

1981
Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.
    International journal of clinical pharmacology, therapy, and toxicology, 1984, Volume: 22, Issue:9

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Drug Therapy, Combination; Female; Heterozygote; Homozygote; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Naphthalenes

1984
Effects of probucol on homozygous cases of familial hypercholesterolemia.
    Atherosclerosis, 1983, Volume: 48, Issue:2

    Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol; Energy Intake; Female; Homozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phenols; Plasma Exchange; Probucol; Skin Diseases; Tendons; Triglycerides; Xanthomatosis

1983
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
    The New England journal of medicine, 1983, Mar-17, Volume: 308, Issue:11

    Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Drug Evaluation; Drug Therapy, Combination; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phospholipids; Triglycerides

1983
Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia.
    The Journal of clinical investigation, 1981, Volume: 67, Issue:5

    Topics: Anticholesteremic Agents; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Naphthalenes; Sterols

1981
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.
    The New England journal of medicine, 1981, 08-27, Volume: 305, Issue:9

    Topics: Adult; Aged; Cholesterol; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Naphthalenes; Triglycerides; Ubiquinone

1981
Effects of probucol on xanthomata regression in familial hypercholesterolemia.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Drug Therapy, Combination; Female; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Phenols; Plasmapheresis; Probucol; Xanthomatosis

1986
Regulation of synthesis and cell content of the low-density-lipoprotein receptor protein in cultured fibroblasts from normal and familial hypercholesterolaemic subjects.
    European journal of biochemistry, 1987, Feb-16, Volume: 163, Issue:1

    Topics: Acetates; Cell Membrane; Cells, Cultured; Cholesterol; Fibroblasts; Humans; Hyperlipoproteinemia Type II; Immunochemistry; Lipoproteins; Lovastatin; Methionine; Naphthalenes; Radioimmunoassay; Receptors, LDL

1987
Drugs inhibiting HMG-CoA reductase.
    Pharmacology & therapeutics, 1985, Volume: 31, Issue:3

    Topics: Animals; Anticholesteremic Agents; Cells, Cultured; Chemical Phenomena; Chemistry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Naphthalenes; Sterols

1985
HMG-CoA reductase inhibitors.
    Advances in experimental medicine and biology, 1985, Volume: 183

    Topics: Animals; Cell Division; Cells, Cultured; Cholesterol; Drug Resistance; Enzyme Induction; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Naphthalenes; Structure-Activity Relationship

1985